Amicus Therapeutics Stock In The News
| FOLD Stock | USD 9.41 0.05 0.53% |
Our overall analysis of Amicus Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Amicus Therapeutics. The specific impact of Amicus Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Amicus Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Amicus Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Amicus Therapeutics Backtesting and Amicus Therapeutics Hype Analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
Amicus |
Amicus Therapeutics Today Top News and Investor Outlook
Amicus Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Amicus and other traded companies coverage with news coverage. We help investors stay connected with Amicus headlines for the 19th of January to make an informed investment decision based on correlating the impacts of news items on Amicus Stock performance. Please note that trading solely based on the Amicus Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Amicus Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Amicus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Amicus Therapeutics that are available to investors today. That information is available publicly through Amicus media outlets and privately through word of mouth or via Amicus internal channels. However, regardless of the origin, that massive amount of Amicus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Amicus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Amicus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Amicus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Amicus Therapeutics alpha.
Amicus Largest EPS Surprises
Earnings surprises can significantly impact Amicus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2024-08-08 | 2024-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2023-11-08 | 2023-09-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2021-11-09 | 2021-09-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2023-08-08 | 2023-06-30 | -0.12 | -0.15 | -0.03 | 25 | ||
2023-05-10 | 2023-03-31 | -0.15 | -0.18 | -0.03 | 20 |
Amicus Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Amicus Therapeutics Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
17th of January 2025
Amicus Therapeutics, Inc. The Biotech Stock with Biggest Upside Potential at finance.yahoo.com
13th of January 2025
Avanzanite Bioscience Announces Appointment of Chief Technical Officer to Accelerate Europ... at businesswire.com
8th of January 2025
In His Amicus Brief Trump Tells SCOTUS That The Copia Institute Is Right at techdirt.com
3rd of January 2025
Acquisition by Simon Harford of 150517 shares of Amicus Therapeutics at 9.41 subject to Ru... at MacroaxisInsider
2nd of January 2025
Disposition of 7482 shares by Simon Harford of Amicus Therapeutics at 9.31 subject to Rule... at gurufocus.com
24th of December 2024
Manifold Finance Self Reported Market Cap Achieves 133.07 Million at thelincolnianonline.com
20th of December 2024
Virtu Financial LLC Invests 107,000 in Amicus Therapeutics, Inc. at thelincolnianonline.com
3rd of December 2024
Amicus Capital Group Acquires Case Compass A Transformative Move in Legal Technology at prnewswire.com
7th of November 2024
Heres What Key Metrics Tell Us About Amicus Therapeutics Q3 Earnings at finance.yahoo.com
4th of November 2024
AbCellera Biologics Inc. Reports Q3 Loss, Misses Revenue Estimates at finance.yahoo.com
Amicus Therapeutics Investors Sentiment
The influence of Amicus Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amicus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amicus Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amicus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amicus Therapeutics' short interest history, or implied volatility extrapolated from Amicus Therapeutics options trading.
Check out Amicus Therapeutics Backtesting and Amicus Therapeutics Hype Analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share | Quarterly Revenue Growth 0.367 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.